Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Clinical trial NCT04220866 · COMPLETED
Trial details
- NCT number
- NCT04220866
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-04
- Primary completion
- 2022-09-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.